E-mail: info@psoriasisaustralia.org.au    |
Targeting much more than ‘influenza of the skin’ – New biologic for chronic plaque psoriasis set to be PBS listed

A new targeted biologic for the estimated 19,000 Australian adults living with severe chronic plaque psoriasis1 will be listed on the Pharmaceutical Benefits Scheme (PBS) on February 1, 2019 for those who meet the reimbursement criteria. ILUMYA™ (tildrakizumab) belongs to a new class of biologic medicines, known as interleukin (IL) inhibitors, that specifically block a…

January 27, 2019
Medicines for the treatment of psoriasis listed on the PBS

The Liberal National Government will make two new medicines for the treatment of the skin condition psoriasis more affordable, saving patients up to $32,600 per year. The medicine Tremfya® (Guselkumab) is being listed on the Pharmaceutical Benefits Scheme (PBS) from February 1 for the treatment of severe chronic plaque psoriasis. The medicine would cost around…

January 27, 2019